Ethics Governance
Ethics & Governance - Resources and Articles |
| Articles indexes: a | b | c | d | e | f | g | h | i | j | k | l | m | n | o | p | q | r | s | t | u | v | w | x | y | z | other | |
|
|
| Article - Abstract. To view full article click on the article title. | |
eMJA: Studdert & Brennan, Clinical trials in developing countries: scientific and ethical issues Clinical trials in developing countries: scientific and ethical issues David M Studdert and Troyen A Brennan Since the 1994 finding that intensive zidovudine treatment of mothers and infants can dramatically reduce perinatal transmission of human immunodeficiency virus, this treatment has been widely adopted in developed countries. In developing countries, trials of less-intensive (and cheaper) regimens have gone ahead, many funded by foreign governments and the United Nations. Controversy has erupted over these trials, particularly over their use of placebo controls. Do differences in healthcare needs and budgets justify different ethical standards in the developed and the developing world? MJA 1998; 169: 545-548For editorial comment, see McNeill Controversy over AIDS clinical trials in developing countries has galvanised public attention and divided the medical research community.1-4 The trials in question, in sub-Saharan Africa and Thailand, use randomised, placebo-controlled methods to test the effectiveness of interventions in preventing perinatal transmission of human immunodeficiency virus (HIV).5,6 At least nine of these trials have received US government funding through the Centers for Disease Control (CDC) or National Institutes of Health (NIH), while five are funded by other foreign governments, and one by the United Nations Program on AIDS (UNAIDS). Background to the controversy is shown in the Box. Debate was sparked in September 1997 by an article5 and an editorial13 in the New England Journal of Medicine. Full Article: http://www.mja.com.au/public/issues/nov16/studdert/studdert.html |
|
2006 Ethics-Governance.com |
|||